Retatrutide and the Rise of the Triple Agonist

Semaglutide activates one metabolic receptor. Tirzepatide activates two. Retatrutide activates three — GLP-1, GIP, and glucagon — from a single once-weekly molecule, and that third receptor is what has metabolic researchers paying such close attention. Developed by Eli Lilly under the code name LY3437943, retatrutide is the most advanced "triple agonist" in clinical development, with phase-2 results that reset expectations for what a weight-management drug can do in a trial setting.

There is one thing to be clear about before the numbers: retatrutide is an investigational drug. It is not FDA-approved for any use or any indication, it cannot be prescribed outside a clinical trial, and Promise does not offer it. What follows is an explanation of how it works, what the trials have measured so far, and where the story goes next.

What retatrutide is

Retatrutide is an investigational once-weekly injectable peptide from Eli Lilly that acts as an agonist at three receptors at once: GLP-1, GIP, and the glucagon receptor (GCGR). It has completed phase-2 trials in obesity, type 2 diabetes, and metabolic liver disease, and is now in phase-3 registrational trials.

The molecule moved from discovery through clinical proof-of-concept in work published by Lilly scientists in 2022. Its design belongs to a broader class of gut-hormone polyagonists — engineered peptides that combine several hormone signals in one structure. A 2024 review of multi-receptor obesity drugs argues that this class can reach 20–30% weight reduction in trials, positioning polyagonist pharmacotherapy as a potential alternative to bariatric surgery.

Three receptors, one molecule

Retatrutide's mechanism combines the actions of three hormones the body already uses to manage food intake, blood sugar, and energy expenditure. Each receptor contributes something the others do not, which is the entire argument for building a triple agonist instead of stopping at one or two.

GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by L-cells in the intestine when nutrients arrive. Activating its receptor prompts the pancreas's beta-cells to release insulin — but only when blood sugar is elevated — while also suppressing glucagon secretion from alpha-cells, slowing gastric emptying, and promoting satiety through receptors in the brain's appetite-regulating centers, the brainstem and hypothalamus (two recent reviews map these four mechanisms in detail).

GIP (glucose-dependent insulinotropic polypeptide) is the second incretin, secreted by intestinal K-cells. It strengthens the meal-triggered, glucose-dependent release of insulin, working additively with GLP-1 — in research models, as much as 70% of the insulin released after eating traces back to these two hormones acting in concert (a 2023 mechanistic review). In fat tissue, activating the GIP receptor sets off futile cycling of calcium through SERCA pumps, which spends cellular energy; preclinically it also suppresses food intake while boosting lipid oxidation and thermogenesis. GIP even seems to blunt the nausea and vomiting GLP-1 can cause — an effect shown across three lab species (mouse, rat, and musk shrew) without losing the appetite or glucose benefits (the key animal study).

Glucagon (GCGR) is the surprising ingredient. Glucagon is the alpha-cell hormone that canonically raises blood glucose by driving the liver to release stored glycogen. Inside a polyagonist, though, its receptor contributes what GLP-1 and GIP cannot: liver-centered mechanisms that raise calorie burn, stimulate lipolysis and the oxidation of hepatic fat, and strongly lower lipids. Experiments with LY3324954 — a research tool that activates the glucagon receptor over a long duration — lowered both blood cholesterol and triglycerides in the livers of diet-induced-obese mice, dose-dependently and through a route separate from the energy-expenditure effect; the same line of work found that glucagon's boost to energy expenditure showed up preferentially in obese animals rather than lean ones (the glucagon-receptor tool study; a 2025 review of triple-agonism therapies).

The balancing act matters. Too much glucagon activity on its own would risk hyperglycemia; in a triple agonist it is offset by the GLP-1 and GIP components, and because incretin signaling is glucose-dependent — active mainly when blood sugar is high — the combination is designed to mitigate hypoglycemia risk in research models. The proposed advantage of integrating all three signals is acting on glucose control, fat storage, appetite, and energy use all at once, which may blunt the compensatory adaptations — hunger rebound, metabolic slowdown — that limit single-pathway interventions. That framing remains a mechanistic hypothesis being tested in phase 3.

How single, dual, and triple agonists compare

A single GLP-1 agonist, a dual GLP-1/GIP agonist, and a triple GLP-1/GIP/glucagon agonist differ mainly in energy expenditure and lipid effects: each added receptor recruits a metabolic pathway the previous generation left untouched. The table below summarizes the mechanistic differences across the three generations.

A single GLP-1 agonist delivers meaningful glucose and body-composition effects but adds little energy expenditure; the earliest compounds required daily injections, and later analogs stretched to once-weekly dosing by engineering the peptide backbone to withstand enzymatic breakdown (a 2024 clinical review). Adding GIP brought a synergistic insulinotropic effect, energy expenditure in adipose tissue, and better GI tolerability — in trials of dual agonists, HbA1c fell dose-dependently by as much as 2.06% relative to placebo, with stronger body-composition changes than GLP-1 alone (dual-agonist data reviewed in 2024).

Adding glucagon is the critical differentiator. In head-to-head animal work, triple GLP-1/GIP/glucagon agonists brought the body weight of diet-induced-obese mice fully back to normal — beating single GLP-1 agonists, GLP-1/GIP duals, and GLP-1/glucagon pairings — with the extra energy burn confirmed by two independent measures, respiratory quotient and direct calorimetry; the animals also ate less, handled glucose better, and accumulated less fat in the liver (the 2022 head-to-head study). Animal results do not always translate to human outcomes — but for retatrutide, the human data has now arrived in volume.

What the phase-2 trials measured

Retatrutide's phase-2 program produced three headline trials — obesity, type 2 diabetes, and metabolic liver disease — each randomized, double-blind, and controlled. The numbers below are trial averages in the populations studied; they describe what participants experienced, not what any individual should expect.

Obesity (48 weeks). In the phase-2 obesity trial, published in 2023, adults with obesity taking the 12 mg dose lost an average of 24.2% of their body weight over the trial's 48 weeks, while the placebo group averaged 2.1%. The authors noted that, at publication, no drug trial had reported a larger average weight loss. At that dose and duration, every participant (100%) lost at least 5% of body weight, 93% lost at least 10%, and 83% lost at least 15%. Waist circumference shrank in step with dose; non-HDL cholesterol fell by as much as 26.9%; systolic blood pressure came down by as much as 14 mmHg on the top dose; and roughly 72% of participants who started with prediabetes returned to normal blood sugar. Weight was still falling at week 48 with no plateau in sight, and side effects were mostly digestive, mild or moderate in severity, and in line with what the incretin class typically shows.

Type 2 diabetes (36 weeks). The phase-2 diabetes trial — which measured retatrutide against both placebo and the GLP-1 drug dulaglutide over 36 weeks — found that the 12 mg dose lowered HbA1c by roughly 2.0 percentage points, brought as many as 82% of participants to an HbA1c of 6.5% or lower, and produced a 16.94% average weight reduction in this diabetes population.

Metabolic liver disease (phase 2a). A randomized phase-2a trial enrolled 98 participants with metabolic dysfunction-associated steatotic liver disease (MASLD). On the 12 mg dose, liver fat dropped 82.4% from its baseline level by week 24, while the placebo arm's rose 0.3%; 86% of the 12 mg group reached normal liver fat (below 5%), against 0% on placebo; and by week 48, steatosis had cleared in over 85% of those studied. Insulin resistance measured by HOMA2-IR fell by up to 69.3%. Researchers point to what glucagon is long known to do — drive fat oxidation in the liver and mobilize stored energy — as the mechanistic explanation for results of this size.

Pooled analysis. A 2025 systematic review and meta-analysis pooled 878 participants from three randomized controlled trials and found that, relative to placebo across doses and populations, weight fell by a mean of 14.33%, BMI dropped 5.38 kg/m², and fasting glucose came down 23.51 mg/dL; by week 36, as many as 63% of pooled participants had reached the 15% weight-loss mark.

The TRIUMPH phase-3 program

TRIUMPH is retatrutide's registrational phase-3 program: four trials enrolling upward of 5,800 people in total, spanning cardiovascular disease, obesity, knee osteoarthritis, and obstructive sleep apnea, and designed to generate the evidence base regulators will ultimately rule on (the TRIUMPH design paper).

The first topline result arrived in December 2025. In TRIUMPH-4 — a 68-week trial of 445 adults with obesity or overweight plus moderate-to-severe knee osteoarthritis, without diabetes — participants on the 12 mg dose lost an average of 28.7% of body weight (26.4% at 9 mg, and up to 71.2 lb in absolute terms), which Lilly characterized as the biggest average weight reduction any phase-3 drug trial had recorded to date (Lilly's December 11, 2025 announcement).

A caution on reading that number: TRIUMPH-4 ran 20 weeks longer than the phase-2 obesity trial and enrolled a different population, so the 28.7% at 68 weeks is not a like-for-like upgrade of the 24.2% at 48 weeks. Trial durations and populations travel with their numbers, and the remaining TRIUMPH readouts — including the core obesity and cardiovascular trials — are still ahead. (For a sense of how a registrational program of this kind unfolds, tirzepatide's clinical trials ran the same gauntlet a few years earlier.)

Open questions the trials still have to answer

Retatrutide's remaining questions are the ones any triple agonist faces: receptor balance, tolerability at scale, and durability. The phase-2 data is strong, but phase 3 exists precisely because promising mid-stage results sometimes narrow when tested in larger, longer, more diverse populations.

The specific open items researchers flag: balancing receptor activation, since excess glucagon activity risks hyperglycemia if not offset by adequate incretin action; monitoring gastrointestinal and metabolic side effects across bigger populations; the translational gap, because animal findings — including the striking weight normalization in obese mice — do not always carry over to human outcomes; and fine-tuning doses, building longitudinal safety data, and exploring targeted tissue delivery, all of which remain active research areas.

The wider polyagonist landscape

Retatrutide is the furthest along, but it is one entry in a broader wave of multi-receptor metabolic research. Cagrilintide, an amylin analog acting on distinct receptor pathways that modulate appetite and gastric emptying, is under study alongside GLP-1 agonists for possible additive effects. Researchers have also examined non-incretin peptides such as AOD9604, a truncated piece of the human growth hormone molecule investigated for lipid-metabolism effects without full-length growth hormone's growth-promoting properties. And an NIH group has reported that multi-agonist peptides built on incretin biology protect neurons and damp inflammation in cellular models of neurodegeneration — early-stage work, but a sign of how far beyond weight the receptor biology may reach (the NIH group's report).

What you can do today

Retatrutide cannot be part of anyone's treatment plan yet — but the incretin system it targets is already reachable. Semaglutide, a single GLP-1 agonist, and tirzepatide, a dual GLP-1/GIP agonist, are available today through licensed providers, and both belong to the same family of medicines whose furthest edge retatrutide represents. (How those two differ in practice is covered in our tirzepatide vs semaglutide comparison.) Through Promise, each is dispensed as a compounded medication, which is different from an FDA-approved product: the formulations offered here are not FDA-approved.

If the trial results above are what brought you here, the practical next step is a conversation about the options that exist now — your health history, your goals, and whether an incretin-based medication makes sense for you at all. A licensed provider reviews every request; not everyone qualifies, and a provider may decline based on your health history.

Watching the phase-3 story

The next two years decide what retatrutide becomes. TRIUMPH-4's 28.7% topline is one readout of four; the core obesity trial, the sleep-apnea trial, and the cardiovascular-outcomes trial are still maturing, and only after the program completes does a regulatory submission — and any decision on approval — follow. The pattern worth watching is whether the phase-2 signal holds its size in larger, longer, more varied populations, and whether the three-receptor balance stays clean at scale.

In the meantime, the incretin era is already here in prescribable form. If retatrutide's trial story has you thinking about your own metabolic health, that conversation does not need to wait for phase 3.

References

1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 2023. https://pubmed.ncbi.nlm.nih.gov/37366315/
2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled phase 2 trial. The Lancet, 2023. https://pubmed.ncbi.nlm.nih.gov/37385280/
3. Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 2024. https://pubmed.ncbi.nlm.nih.gov/38858523/
4. Abouelmagd AA, et al. Efficacy and safety of retatrutide: a systematic review and meta-analysis. Proceedings of Baylor University Medical Center, 2025. https://pubmed.ncbi.nlm.nih.gov/40291085/
5. Giblin K, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism, 2026. https://pubmed.ncbi.nlm.nih.gov/41090431/
6. Eli Lilly and Company. Investor press release: TRIUMPH-4 topline results. December 11, 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
7. Coskun T, et al. LY3437943: discovery through clinical proof of concept. Cell Metabolism, 2022. https://pubmed.ncbi.nlm.nih.gov/35985340/
8. Kusminski CM, Perez-Tilve D, Müller TD, DiMarchi RD, et al. Transforming obesity: The advancement of multi-receptor drugs. Cell, 2024. https://pubmed.ncbi.nlm.nih.gov/39059360/
9. Liu QK. Frontiers in Endocrinology, 2024. https://pubmed.ncbi.nlm.nih.gov/39114288/
10. Alfaris N, et al. Narrative review of single, dual, and triple incretin receptor agonists. EClinicalMedicine, 2024. https://pubmed.ncbi.nlm.nih.gov/39281096/
11. Jakubowska A, le Roux CW, Viljoen A. Endocrinology and Metabolism, 2024. https://pubmed.ncbi.nlm.nih.gov/38356208/
12. Gutgesell RM, et al. Diabetes Therapy, 2024. https://pubmed.ncbi.nlm.nih.gov/38573467/
13. Campbell JE, et al. Cell Metabolism, 2023. https://pubmed.ncbi.nlm.nih.gov/37591245/
14. Borner T, et al. Diabetes, 2021. https://pubmed.ncbi.nlm.nih.gov/34380697/
15. Knerr PJ, et al. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Molecular Metabolism, 2022. https://pubmed.ncbi.nlm.nih.gov/35809773/
16. Roell W, et al. Molecular Metabolism, 2025. https://pubmed.ncbi.nlm.nih.gov/39603505/
17. Goldney J, et al. Triple Agonism Based Therapies for Obesity. Current Cardiovascular Risk Reports, 2025. https://pubmed.ncbi.nlm.nih.gov/40741227/
18. Kopp KO, et al. Biomolecules, 2024. https://pubmed.ncbi.nlm.nih.gov/39062586/
19. Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes, Obesity and Metabolism, 2018. https://pubmed.ncbi.nlm.nih.gov/29364588/

This article is for informational purposes only and is not medical advice. Talk to a licensed healthcare provider about your health and any treatment decisions.

by Elena Marsh, Health Writer